- Home
- PCRX vs CRGX Comparison
PCRX vs CRGX Comparison
Compare PCRX & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- CRGX
- Stock Information
- Founded
- PCRX 2006
- CRGX 2021
- Country
- PCRX United States
- CRGX United States
- Employees
- PCRX N/A
- CRGX N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- CRGX
- Sector
- PCRX Health Care
- CRGX
- Exchange
- PCRX Nasdaq
- CRGX Nasdaq
- Market Cap
- PCRX 1.2B
- CRGX 628.6M
- IPO Year
- PCRX 2011
- CRGX 2023
- Fundamental
- Price
- PCRX $26.59
- CRGX $3.70
- Analyst Decision
- PCRX Buy
- CRGX Hold
- Analyst Count
- PCRX 10
- CRGX 7
- Target Price
- PCRX $29.30
- CRGX $4.67
- AVG Volume (30 Days)
- PCRX 892.8K
- CRGX 1.9M
- Earning Date
- PCRX 02-27-2025
- CRGX 03-20-2025
- Dividend Yield
- PCRX N/A
- CRGX N/A
- EPS Growth
- PCRX N/A
- CRGX N/A
- EPS
- PCRX N/A
- CRGX N/A
- Revenue
- PCRX $694,957,000.00
- CRGX N/A
- Revenue This Year
- PCRX $5.14
- CRGX N/A
- Revenue Next Year
- PCRX $2.44
- CRGX N/A
- P/E Ratio
- PCRX N/A
- CRGX N/A
- Revenue Growth
- PCRX 4.40
- CRGX N/A
- 52 Week Low
- PCRX $11.16
- CRGX $3.00
- 52 Week High
- PCRX $31.67
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- PCRX 77.75
- CRGX 20.88
- Support Level
- PCRX $25.06
- CRGX $3.00
- Resistance Level
- PCRX $27.10
- CRGX $3.88
- Average True Range (ATR)
- PCRX 1.45
- CRGX 0.92
- MACD
- PCRX 0.28
- CRGX -1.00
- Stochastic Oscillator
- PCRX 86.23
- CRGX 5.99
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.